Filing summary
Impact BioMedical Inc. (NYSE American: IBO) filed this Form 8-K on October 9, 2026, reporting a reverse stock split that became effective September 23, 2026. The filing concerns a corporate action, not a financial-results period.
Reverse stock split
- The company effected a 1-for-12.62 reverse split of its issued and outstanding common stock. The ratio was within the range previously authorized by the board and approved by stockholders.
- Outstanding common shares decreased from approximately 107.8 million to approximately 8.6 million.
- Authorized share counts, par value, and common-stock voting rights were unchanged. No fractional shares were issued; holders otherwise due a fractional share received one full post-split share.
- The stock continued trading under ticker IBO on a split-adjusted basis, with a new CUSIP number, 45259L304.
Timing and other disclosures
The company said a clerical processing error at the Nevada Secretary of State delayed its receipt of the file-stamped amendment until October 6, 2026. As a result, it filed this report later than four business days after the September 23 event and said it had contacted NYSE American regarding the matter.
Registered holders in book-entry form and holders through brokers or other nominees generally did not need to take action, though nominee processing may vary. The transfer agent, Equiniti Transfer & Trust Company, served as exchange agent.
Financial metrics and outlook
This filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, guidance, or operating outlook. It does not quantify any financial impact of the reverse split.
Key facts to verify
- Confirm the effective split ratio, adjusted share count, and treatment of fractional entitlements with the company or transfer agent.
- Confirm that brokerage positions and market data reflect the split and new CUSIP.
- Review Exhibit 3.1, the filed certificate amendment, and any related NYSE American notices.